Scholarlink

<p>Human milk oligosaccharides (HMOs) are a crucial ingredient in mother’s milk for infant health. These are a structurally diverse group of soluble bioactive glycans having antiviral and anti-bacterial properties and promote the growth of probiotics, particularly <i>Bifidobacteria</i>. They modulate the immune system and are important for infant’s brain development. Not all infants are fortunate enough to receive mother milk, and rely on industrially produced infant formulas which lack HMOs. Thus, synthesizing HMOs through different methods is becoming more appealing form an industrial perspective.&#xa0;Despite huge efforts to obtain predominant HMOs through chemical,&#xa0;chemo-enzymatic, enzymatic, and whole-cell biotransformation of microorganisms, a limited number of HMOs could be produced in sufficient quantities due to lack of canonical enzymes that can add different metabolic pathways together to produce several HMO. Particularly, lacto-N-neotetraose and 2′-fucosyllactose are being added to infant formula and are well-tolerated by infants. Amide other methods, enzymatic and whole-cell biotransformation of microorganisms are promising approaches, but it requires intervention of innovative methodologies of synthetic biology. This review highlights innovative approaches, such as using plant system, and employing synthetic biology including redesigning of enzyme structure for producing HMOs at the industrial level. An interesting approach for synthesizing whole milk components in mammary cell lines is also mentioned.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Synthesising human milk oligosaccharide using biotechnology-driven enzymes

  • 期刊论文

  • 发表日期：

    2025年1月28日

查看全文
  • Jayashree Niharika,
  • Ravindra Pal Singh

摘要

Human milk oligosaccharides (HMOs) are a crucial ingredient in mother’s milk for infant health. These are a structurally diverse group of soluble bioactive glycans having antiviral and anti-bacterial properties and promote the growth of probiotics, particularly Bifidobacteria. They modulate the immune system and are important for infant’s brain development. Not all infants are fortunate enough to receive mother milk, and rely on industrially produced infant formulas which lack HMOs. Thus, synthesizing HMOs through different methods is becoming more appealing form an industrial perspective. Despite huge efforts to obtain predominant HMOs through chemical, chemo-enzymatic, enzymatic, and whole-cell biotransformation of microorganisms, a limited number of HMOs could be produced in sufficient quantities due to lack of canonical enzymes that can add different metabolic pathways together to produce several HMO. Particularly, lacto-N-neotetraose and 2′-fucosyllactose are being added to infant formula and are well-tolerated by infants. Amide other methods, enzymatic and whole-cell biotransformation of microorganisms are promising approaches, but it requires intervention of innovative methodologies of synthetic biology. This review highlights innovative approaches, such as using plant system, and employing synthetic biology including redesigning of enzyme structure for producing HMOs at the industrial level. An interesting approach for synthesizing whole milk components in mammary cell lines is also mentioned.